Overview

NIDDM and IR in Combination Therapy for CHC

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of combination therapy on HOMA IR
Phase:
N/A
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborator:
National Science Council, Taiwan
Treatments:
Interferon-alpha
Interferons
Ribavirin